Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 6/20 | 0.36 |
| ▸ | CTSS | P25774 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17228791 | 0.81 | CTSK (0.43) | CA1CA7CA12CA14CTSK | |
| SCHEMBL3528175 | 0.81 | L3MBTL1 (0.49) | L3MBTL1HTTCA1CA7CA12 | |
| SCHEMBL22644337 | 0.80 | APLNR (0.40) | L3MBTL1HTTCA1CA7CTSK | |
| SCHEMBL2187338 | 0.76 | NPC1 (0.36) | CA1CA7CA12CA14CTSK | |
| SCHEMBL5169401 | 0.76 | CTSS (0.37) | CA1CA7CTSKCTSSTDP1 | |
| SCHEMBL20684929 | 0.75 | HTT (0.31) | L3MBTL1HTTAPLNR | |
| SCHEMBL11412219 | 0.75 | L3MBTL1 (0.45) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL4616898 | 0.74 | CA1 (0.42) | L3MBTL1CA1CA7CA12CA14 | |
| SCHEMBL29168310 | 0.73 | CA1 (0.39) | CA1CA7CA12CA14CTSK | |
| SCHEMBL27636963 | 0.72 | CA1 (0.41) | HTTCA1CA7CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | L3MBTL1 2757/4885HTT 3613/4885CA1 4815/4885 |
| US-11377431-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | L3MBTL1 2757/4885HTT 3613/4885CA1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.